(November 1, 2021)
Solar simulated ultraviolet radiation inactivates HCoV-NL63 and SARS-CoV-2 coronaviruses at environmentally relevant doses Journal of Photochemistry and Photobiology (2021) Sep 21;224:112319 PMID: 34598020
Dual Amelioration of Neurofibrillary tangles and Amyloid plaques with DYR219: A Potent and Selective Small Molecule for DYRK1A at the 2021 Arizona Alzheimer’s Consortium Tucson Conference. Fistrovich, A.; Foley, C.; Velazquez R..; Meechoovet, B.; Ow, A.; Shaw, A.; Smith, B.; Oddo, S.; Gokhale, V.; Dunckley, T.; Christopher Hulme, PhD
Novel Fragments Targeting DYRK1A as Platform Chemotypes for AD Drug Discovery at the 2021 Arizona Alzheimer’s Consortium Tucson Conference. Schofield, K.; Chavez, T.; Gokhale, V.; Shaw, A.; Rokey, S.; Christopher Hulme, PhD
The Development of a Highly Selective, well-tolerated and Orally Bioavailable Inhibitor of DYRK1A for Treatment of Alzheimer’s Disease – DYR533 at the 2021 Arizona Alzheimer’s Consortium Tucson Conference. Rokey, S.; Foley, C.; Velasquez, R.; Dunckley, T.; Shaw, A.; Meechoovet, B.; Christopher Hulme, PhD
Synthesis of high affinity DYRK PROTACS towards treatment of Alzheimer’s disease and SARS-CoV-2 at the 2021 Arizona Alzheimer’s Consortium Tucson Conference. Maddern, S.; Schofield, K.; Chavez, T.; Shaw, A.; Christopher Hulme, PhD
Celina Zerbinatti, PhD has been appointed to be a member of the HealthTech Connect Faculty Executive committee. HealthTech Connect is a community-based consortium founded by UA Health Sciences, designed to build opportunities for the startup, corporate, higher education, health care, funding, and economic development communities to advance Arizona’s cutting-edge innovations in health technology.
Wafaa Alabsi, Pharmaceutics/PK graduate student, passed her PhD defense on 9/27/21. Dr. Alabsi is currently employed in the Mansour Lab as Postdoctoral Research Associate.